17,261 trials
Systemic Lupus Erythematosus
Primary: Percentage of Participants Achieving an Systemic Lupus Erythematosus (SLE) Responder Index [SRI (4)] Response With Oral Corticosteroids (OCS) Tapering at Day 169 — 17.6…
Alcohol Drinking
Primary: Alcohol Consumption — 92.0; 77.3 mg/%
Chronic Oral Food Refusal
Primary: % Calories Taken Orally — 68.62; 76.89 change in percent kcal obtained orally
Advanced Nonhematological Malignancies · Non-Small Cell Lung Cancer · Small Cell Lung Cancer
Primary: Phase 1: Number of Participants With Dose-Limiting Toxicities (DLTs) — 0; 0; 0; 2 participants
Prevention From Norovirus Infection
Primary: Percentage of Participants With Viral AGE Clinical Illness and Fecal Virus Excretion Detected by RT-PCR OR 4-Fold Rise In Anti-GII.4 Norovirus P Particle Antibody Titer…
Substance Use Disorders
Primary: Mean Number of Alcohol and Drug Use Days Out of Past 30 — 1.44; 3.89; 4.65; 3.06 number of days out of past 30
Sarcoidosis, Pulmonary
Primary: The Steroid Sparing Period — 301; 257 days
Malignant Solid Tumor - Malignant Nervous System Neoplasm
Primary: Phase 1: Maximum Tolerated Dose of Cabazitaxel — 30 mg/m^2
Bronchiolitis
Primary: Respiratory Rate — -3.7; -1.7 Percentage change in respiratory rate
Chronic Pain
Primary: Brief Pain Inventory-interference Subscale — 5.3; 5.8 units on a scale — p=0.12
Colorectal Cancer
Primary: Evaluate Whether 2.0g of Ginger Taken Daily, Standardized to 5%-Gingerols for Four Weeks Will Result in Bioactive Levels in Colonic Tissue Sufficient to Reduce Mucosal…
Multiple Myeloma
Primary: Percentage of Participants With Response, Analyzed Per International Myeloma Working Group Response Criteria — 15.8; 20.0 percentage of participants
Fetal Alcohol Spectrum Disorders · Fetal Alcohol Syndrome · Partial Fetal Alcohol Syndrome
Primary: Side Effects of Choline Bitartrate — 8; 10; 8; 9 participants
Obesity · Overweight · Craniopharyngioma
Primary: Body Weight (kg) — -1.4 kg
Colorectal Cancer
Primary: Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 — 10.09; 12.55 months — p=0.0555